Publication | Open Access

Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study

InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseGranulocytePhase 2BRheumatic DiseasesImmunologyAutoimmunityInflammatory Rheumatic DiseaseDose-ranging StudyImmunotherapyMedicineRheumatoid Arthritis